MedTrace Logo

Durability of Nevirapine-Based Antiretroviral Regimen

NCT00703898 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2008-07-08

No results posted yet for this study

Summary

Although nevirapine is used as an alternative to efavirenz for initial regimen in developed countries, nevirapine has still been a key antiretroviral drug in many resource-limited countries including Thailand due to its accessibility and affordability. In addition, a component of stavudine and lamivudine is still widely used as a backbone in the antiretroviral regimen in this setting.To date, data on the durability of a regimen of stavudine, lamivudine and nevirapine are very limited, particularly from the resource-limited settings.

Conditions

  • HIV Infections

Interventions

DRUG

nevirapine

200 mg/day twice a day

Sponsors & Collaborators

  • Bamrasnaradura Infectious Diseases Institute

    lead OTHER_GOV

Principal Investigators

  • Weerawat Manosuthi · Bamrasnaradura Infectious Diseases Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2009-12-31
Completion
2010-04-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00703898 on ClinicalTrials.gov